Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/4439
A61K-009/20
A61K-009/48
A61K-009/50
A61K-009/00
출원번호
US-0138763
(2005-05-25)
등록번호
US-8906940
(2014-12-09)
발명자
/ 주소
Olmstead, Kay
Hall, Warren
Proehl, Gerald T.
출원인 / 주소
Santarus, Inc.
대리인 / 주소
Novak Druce Connolly Bove + Quigg LLP
인용정보
피인용 횟수 :
0인용 특허 :
139
초록▼
The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other im
The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to, a gastrointestinal disorder or disease in a subject in need thereof.
대표청구항▼
1. A pharmaceutical formulation in a compressed tablet oral dosage form consisting essentially of: (a) about 10 mgs to about 100 mgs of a proton pump inhibitor, wherein the proton pump inhibitor is omeprazole;(b) at least one antacid, wherein the antacid comprises about 400 mgs to about 1400 mgs of
1. A pharmaceutical formulation in a compressed tablet oral dosage form consisting essentially of: (a) about 10 mgs to about 100 mgs of a proton pump inhibitor, wherein the proton pump inhibitor is omeprazole;(b) at least one antacid, wherein the antacid comprises about 400 mgs to about 1400 mgs of NaHCO3;(c) about 2 wt-% to about 8 wt-% of a disintegrant;(d) about 3 wt-% to about 8 wt-% of a binder; and(e) about 0.5 wt-% to about 3 wt-% of a lubricant;wherein the antacid further comprises magnesium hydroxide and the total amount of antacid present in the tablet is about 10 mEg to about 30 mEg;wherein the tablet is a homogeneous blend of omeprazole, antacids, disintegrant, binder, and lubricant; andwherein upon oral administration of the compressed tablet to a fasted human subject, a Tmax of the proton pump inhibitor is obtained within about 45 minutes after administration on day I, and an initial serum concentration of the proton pump inhibitor is greater than 300 ng/ml within 45 minutes after administration; and wherein the compressed tablet has a hardness of between is kPa and 20 kPa. 2. The pharmaceutical formulation according to claim 1, wherein the sodium bicarbonate is present in an amount of at least 700 mgs. 3. The pharmaceutical formulation according to claim 1, wherein the disintegrant is croscarmellose sodium and is present in an amount of about 3 wt-%. 4. The pharmaceutical formulation according to claim 1, wherein the disintegrant is present in an amount of about 3 wt-% to about 5 wt-%. 5. The pharmaceutical composition according to claim 1, wherein the binder is hydroxypropyl cellulose and is present in an amount of about 6 wt-%. 6. The pharmaceutical formulation according to claim 1, wherein the binder is present in an amount of about 5 wt-% to about 8 wt-%. 7. A pharmaceutical formulation in a compressed tablet oral dosage form consisting essentially of: (a) a proton pump inhibitor, wherein the proton pump inhibitor is omeprazole or a salt thereof in an amount of about 20 mgs or about 40 mgs;(b) at least one antacid comprising about 700 mgs to about 1400 mgs of NaHCO3;(c) about 2 wt-% to about 8 wt-% of a disintegrant;(d) about 3 wt-% to about 8 wt-% of a binder; and(e) about 0.5 wt-% to about 3 wt-% of a lubricantwherein the antacid further comprises magnesium hydroxide and the total amount of antacid present in the tablet is about 10 mEq to about 30 mEq; andwherein the tablet is a homogeneous blend of omeprazole, antacids, disintegrant, binder, and lubricant. 8. The pharmaceutical composition of claim 7 wherein: (a) the NaHCO3 is present in an amount of about 1100 mgs to about 1400 mgs;(b) the disintegrant is croscarmellose sodium and is present in an amount of about 3 wt-% to about 5 wt-%; and(c) the binder is hydroxypropyl cellulose and is present in an amount of about 5 wt-% to about 8 wt-%;wherein upon oral administration of the tablet to a fasted human subject, a Tmax of the proton pump inhibitor is obtained within about 45 minutes after administration on day 1. 9. A pharmaceutical formulation in a compressed tablet oral dosage form comprising: (a) about 10 mgs to about 100 mgs of a proton pump inhibitor, wherein the proton pump inhibitor is omeprazole or an enantiomer or salt thereof;(b) about 10-30 mEg of antacid comprising about 400 mgs to about 1400 mgs of NaHCO3;(c) about 2 wt-% to about 8 wt-% of a disintegrant; and(d) about 3 wt-% to about 8 wt-% of a binder,wherein the antacid further comprises magnesium hydroxide;wherein the tablet is a homogeneous blend of omeprazole, antacids, disintegrant, and binder; andwherein the compressed tablet has a hardness of between 15 kPa and 20 kPa. 10. The pharmaceutical formulation according to claim 9, wherein the proton pump inhibitor is omeprazole or a salt thereof. 11. The pharmaceutical formulation according to claim 9, wherein the sodium bicarbonate is present in an amount of about 700 mgs to about 1400 mgs. 12. The pharmaceutical formulation according to claim 9, wherein the disintegrant is croscarmellose sodium and is present in an amount of about 3 wt-%. 13. The pharmaceutical formulation according to claim 9, wherein the disintegrant is present in an amount of about 3 wt-% to about 5 wt-%. 14. The pharmaceutical formulation according to claim 9, wherein the binder is hydroxypropyl cellulose and is present in an amount of about 6 wt-%. 15. The pharmaceutical formulation according to claim 9, wherein the binder is present in an amount of about 5 wt-% to about 8 wt-%. 16. The pharmaceutical formulation of claim 9, wherein the NaHCO3 is present in an amount of about 1100 mgs to about 1400 mgs. 17. The pharmaceutical formulation of claim 16, wherein the disintegrant comprises croscarmellose sodium. 18. The pharmaceutical formulation of claim 17, wherein the croscarmellose sodium is present in an amount of about 3 wt-% to about 5 wt-%. 19. The pharmaceutical composition of claim 18, wherein the binder comprises hydroxypropyl cellulose. 20. The pharmaceutical formulation of claim 19, wherein the hydroxypropyl cellulose is present in an amount of about 5 wt-% to about 8 wt-%. 21. The pharmaceutical formulation of claim 1, wherein the tablet provides greater than 50% release of the proton pump inhibitor in gastrointestinal fluid within about 2 hours. 22. The pharmaceutical formulation of claim 9, wherein the tablet provides greater than 50% release of the proton pump inhibitor in gastrointestinal fluid within about 2 hours.
Whittle Robert R. ; Sancilio Frederick D. ; Stowell Grayson Walker ; Jenkins Douglas John ; Whittall Linda B., Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same.
Robert R. Whittle ; Frederick D. Sancilio ; Grayson Walker Stowell ; Douglas John Jenkins ; Linda B. Whittall, Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same.
Spickett Robert G. W. (Barcelona ESX) Vidal Jose L. F. (Barcelona ESX) Escoi Juan C. (Barcelona ESX), Antacid compositions with prolonged gastric residence time.
Alminger Tomas B. (Lindome SEX) Bergman Rolf A. (Molndal SEX) Bundgaard H. (Horsholm DKX) Lindberg Per L. (Askim SEX) Sunden Gunnel E. (Gothenburg SEX), Certain pyridyl[(methylthio- or methyl sulfinyl)-2 benzimidazol-2-yl]N-methyl phosphonates useful for treating gastric-a.
Fain Gordon L. (Los Angeles CA) Lee David A. (Los Angeles CA) Lindberg Per L. (Askim CA SEX) Sachs George (Cure Wadsworth CA), Compounds including omeprazole in the treatment of glaucoma.
Briving Carin B. (Billdal SEX) Carlsson Stig A. I. (Mlnlycke SEX) Lindberg Per L. (Askim SEX) Mattsson Annie H. (Askim SEX) Nordberg Mats P. (Gothenburg SEX) Wallmark Bjrn M. G. (Mlnlycke SEX), Derivatives of benzimidazoles active as anti-ulcer agents.
Lindberg Per L. (Askim SEX) Sundn Gunnel E. (Gteborg SEX), Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use.
Whittle Robert R. ; Sancilio Frederick D. ; Stowell Grayson Walker ; Jenkins Douglas John ; Whittall Linda B. ; Fontana Steven A., Dry blend pharmaceutical formulations.
Junggren Ulf K. (Mlnlycke SEX) Sjstrand Sven E. (Kungsbacka SEX), Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, their preparation, pharmaceutical preparat.
Shell John W. ; Louie-Helm Jenny, Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter.
Gilis Paul Marie Victor,BEX ; Smans Guido Franciscus,BEX ; Gijs Guido Jozef Maria,BEX, Immediate release pH-independent solid dosage form of cisapride.
Upson James G. (Springdale OH) Russell Carmelita M. (Cincinnati OH), Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress.
Zyck, Daniel J.; Sitler, Daniel J.; Barkalow, David G.; Knutsen, Jonathan J.; Shen, Chungsea A.; Zuehlke, Julius W.; Schnell, Philip G., Method for making coated chewing gum products including a high-intensity sweetener.
Graham Daniel,GBX ; Holt Robert,GBX ; Lindberg Per,SEX ; Taylor Stephen,GBX, Method for preparing a pharmaceutically active enantiomeric or enantiomerically enriched sulfoxide compound by enantios.
Min Dong S. (Seoul KRX) Um Kee A. (Suwon KRX) Kim Yong S. (Suwon KRX) Park Pyong W. (Seoul KRX), Method for preparing enteric-coated oral drugs containing acid-unstable compounds.
Lindberg Per,SEX ; Weidolf Lars,SEX, Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazol.
Brndstrm Arne E. (Gothenburg SEX), Method of synthesis of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl-1H-benzimidazole (omeprazole).
Makino Tadashi (Osaka JPX) Tabata Tetsuro (Osaka JPX) Hirai Shin-Ichiro (Kyoto JPX), Method to stabilize a pharmaceutical composition and its production.
Catrenich Carl E. (Fairfield OH) Nelson Dennis G. A. (West Chester OH), Methods and compositions of diphenyl ether phosphate esters for the treatment of gastrointestinal disorders.
Gary G. Liversidge ; W. Mark Eickhoff ; Kathleen J. Illig ; Pramod Sarpotdar ; Stephen B. Ruddy, Methods for targeting drug delivery to the upper and/or lower gastrointestinal tract.
Brndstrm Arne E. (Gteborg SEX) Carlsson Stig A. I. (Mlnlycke SEX) Kllsson Britt I. M. (Mlndal SEX) Lindberg Per L. (Askim SEX), Novel pharmacologically active compound pyridyl methylsulfinyl benzimidazole.
Kanamaru Tsuneo,JPX ; Nakao Masafumi,JPX ; Tawada Hiroyuki,JPX ; Kamiyama Keiji,JPX, Oxazolone derivatives and their use as anti-Helicobacter pylori agent.
Whittle Robert R. ; Sancilio Frederick D. ; Stowell Grayson Walker ; Jenkins Douglas John ; Whittall Linda B. ; Fontana Steven A., Pharmaceutical unit dosage form.
Cherukuri Subraman R. ; Fuisz Richard C. ; Sanghvi Pradeepkumar P. ; Misra Tushar K. ; Sisak John R., Process for forming chewable quickly dispersing comestible unit and product therefrom.
Fuisz Richard C. ; Cherukuri Subraman R. ; Kota Suresh B. ; Stewart James L., Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom.
Larsson Magnus Erik,SEX ; Stenhede Urban Jan,SEX ; Sorensen Henrik,SEX ; von Unge Sverker Per Oskar,SEX ; Cotton Hanna Kristina,SEX, Process for synthesis of substituted sulphoxides.
Hogberg Jan-.ANG.ke,SEX ; Ioannidis Panagiotis,SEX ; Mattson Anders,SEX, Process for the preparation of a magnesium salt of a substituted sulfinyl heterocycle.
Hoerrner Robert S. (Scotch Plains NJ) Friedman Joel J. (East Brunswick NJ) Amato Joseph S. (Brooklyn NY) Liu Thomas M. (Westfield NJ) Shinkai Ichiro (Westfield NJ) Weinstock Leonard M. (Hilton Head S, Process for the preparation of antiulcer agents.
Debregeas Patrice (Versailles FRX) Leduc Grard (Malesherbes FRX), Stable compositions of gastroprotected omerprazole microgranules and process for the production thereof.
Eek Arne T. (Trosa SEX) Sjostrand Sven E. (Sodertalje SEX), Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic.
Eek Arne T. (Trosa SEX) Sjostrand Sven Erik (Sodertalje SEX), Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic.
Eek Arne T. (Trosa SEX) Sjostrand Sven Erik (Sodertalje SEX), Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic.
Brndstrm Arne E. (Gteborg SEX) Lindberg Per L. (Askim SEX) Starke Carl I. (Gteborg SEX) Sundn Gunnel E. (Gteborg SEX), Therapeutically active chloro substituted benzimidazole.
Brndstrm Arne E. (Gteborg SEX) Lindberg Per L. (Askim SEX) Sunden Gunnel E. (Gteborg SEX), Therapeutically active compound and a process for its preparation.
Johnstone Scott Bowen ; Jones Brad Allen ; Mellon Mark ; Rigby William Roger, Unit dose packaging system (UDPS) having a child resistant locking feature.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.